Secondary immune thrombocytopenia supposedly attributable to COVID-19 vaccination

Omar Fueyo-Rodriguez, 1 Benjamin Valente-Acosta, Rodolfo Jimenez-Soto, Yvette Neme-Yunes, Sergio Ignacio Inclán-Alarcón, Roxana Trejo-Gonzalez, Miguel Ángel García-Salcido

SUMMARY
Immune thrombocytopenia (ITP) has been widely reported as a complication of SARS-CoV-2 infection, but to our knowledge, there have been no reports on the association of the COVID-19 vaccine with thrombocytopenia. Here, we report a case of secondary ITP in a patient who was recently immunised with the messenger RNA COVID-19 vaccine BNT162b2 (Pfizer–BioNTech).

BACKGROUND
There is an ongoing COVID-19 pandemic affecting every country in the world. Over one million people had died from COVID-19 by the beginning of 2021.1 In Mexico, more than 200 000 deaths have been recorded.2 This global health crisis has accelerated scientific funding and cooperation; as a result, many vaccines to prevent COVID-19 have been developed.

One of the first vaccines that received emergency use authorisation in many countries was the messenger RNA (mRNA) COVID-19 vaccine BNT162b2 (Pfizer–BioNTech),3 4 a nucleoside-modified mRNA lipid nanoparticle-formulated vaccine that encodes for SARS-CoV-2 spike protein. Both safety and efficacy have been proven by manufacturer’s clinical trials. In regard to reactogenicity, the most commonly reported events have been pain at the injection site, fatigue, headache, chills, muscle pain and fever.5

As noted by Berlin, low prevalence adverse events are very unlikely to be identified, even in well-designed phase 3 clinical trials; thus, these kinds of events are often identified through post-market surveillance programmes.6 The immune thrombocytopenia (ITP) incidence among adults is 3.3 cases per 100 000 adults/year.7 However, only 37 706 participants received vaccination or placebo and had a follow-up for an average of 2 months in the safety trials.3

ITP is an autoimmune disorder in which autoantibodies inhibit platelet production and impair the circulating platelets. Most cases are related to autoimmunity; however, there are secondary trigger conditions, such as viral infections or even vaccines.8 The present case reports a patient who received the mRNA COVID-19 vaccine BNT162b2 (Pfizer–BioNTech) and subsequently developed secondary ITP.

CASE PRESENTATION
A 41-year-old woman, with history of multiple allergies (quiolones, cephalosporins, strawberries and iodinated contrast), presented to the emergency department with a 12-hour history of fever, tachycardia and nausea. She had a history of hypothyroidism, hypertension and pre-diabetes and was under treatment with enalapril and levothyroxine. She had received the mRNA COVID-19 vaccine BNT162b2 (Pfizer–BioNTech) 12 hours before the symptoms developed.

At her initial evaluation, the patient reported malaise, headache and loose stools on multiple occasions. She did not report urinary or neurological symptoms. She had taken metoprolol for tachycardia and paracetamol to control the fever. She had not taken any other medications.

A physical examination in the emergency department revealed a blood pressure of 154/99 mm Hg, a pulse of 108 beats per minute and an SpO2 of 94% breathing ambient air. Her temperature was 37.4°C. She was alert and oriented. She was mildly dehydrated; otherwise, her physical examination was normal.

INVESTIGATIONS
Initial blood tests showed a normal leucocyte count without lymphopenia; however, moderate thrombocytopenia (65 × 109) was remarkably evident. The patient had a previous blood cell count 4 months ago, where platelet count was normal. Coagulation tests, iron levels and storages were normal. Her C reactive protein and IgE were elevated, but otherwise, all tests were within normal range including C3, C4 levels, antinuclear antibodies, anti–Sjögren’s-syndrome-related antigen A autoantibodies (anti–SSA), anti–Sjögren syndrome antigen B antibodies (anti–SSB) and anti-DNAs. The peripheral smear did not show any alterations. The mean platelet volume was slightly elevated 11.3 fl (normal range 6.5–11.0 fl). We did not perform antiplatelet antibodies or bone marrow smear (table 1).

A nasopharyngeal swab for RT-PCR SARS-CoV-2, an SARS-CoV-2 rapid antigen test and an anti-SARS-CoV-2 IgG test were all negative. A CT scan of the lung showed no evidence of infiltrates or areas of ground glass opacities, and an CT of the abdominal was unremarkable.

TREATMENT
The patient remained in the emergency department, where she was given intravenous fluids...
therapy, analgesic and antipyretic management with paracetamol. After 12 hours in the emergency department, a new blood test revealed a decrease in platelets (38×10⁹). At that point, she developed headache, bleeding gums and petechiae, so we administered 1gm of methylprednisolone. A CT scan of the brain was performed without evidence of intracerebral haemorrhage. Haematology was consulted for suspicion of secondary ITP due to the COVID-19 vaccine. We started targeted treatment with 40mg intravenous dexamethasone daily and intravenous immune globulin (IG) calculated per kilogram of weight (a total dose of 24gm) according to the 2019 international consensus on the investigation and management of primary ITP.

OUTCOME AND FOLLOW-UP
After the first dose of intravenous IG, she presented mild hypertension, so amlopidine was started. She was then admitted to the internal medicine ward for clinical surveillance. After the second dose of dexamethasone and intravenous IG, platelet count began to increase and gingival haemorrhage resolved. She received a total of four doses of dexamethasone and three doses of intravenous IG. Platelet count remained in the normal range, so we were able to discharge her after 5 days. We followed up with an external consultation a week later, where we evidenced a platelet count of 629×10⁹.

DISCUSSION
Many autoimmune effects have been related to vaccines, including type 1 diabetes mellitus, multiple sclerosis, Guillain-Barre syndrome and acute disseminated encephalomyelitis. However, ITP following vaccination has been previously reported in the literature, specifically with measles, mumps and rubella vaccine. Recently, a COVID-19 vaccination-related ITP case has been reported. For most of the cases, a temporal relation has been established, nevertheless, we do not suggest that these findings nor our case have a causative association with the vaccination. There are biological mechanisms that could explain ITP clinical findings that should be explored too, but the aim of this case report is not to establish causation, but to describe our findings and raise awareness for clinical and surveillance purposes.

ITP is an autoimmune disorder in which autoantibodies inhibit platelet production and impair circulating platelets, resulting in thrombocytopenia that is not associated with other haematologic abnormalities. Most cases are related to autoimmunity; however, there are secondary trigger conditions, such as viral infections or vaccines. The main mechanism is of immune origin through the cross-reaction of platelet antibodies with platelet antigens, such as GP Ib/IX, GP Ia/Ila and GP VI. Therefore, there are other antigen responses to vaccine constituents, adjuvants and preservatives or by molecular mimicry, epitope spreading and polyclonal activation.

Reactions can occur shortly after exposure to a trigger. For instance, if the patient has been sensitised by previous exposure to the drug, the onset of thrombocytopenia may be more rapid (eg, as early as hours after exposure). In our case, the patient developed thrombocytopenia in 48 hours, and it is unlikely that previous exposure to the vaccine constituents or adjuvants was involved particularly in our case because it was the vaccine’s first dose, and the patient has no history of COVID-19 infection.

Complications related to this entity might be life-threatening when the platelet count is below 5×10⁹. In contrast, in our patient, the lowest platelet count was 39×10⁹. Therefore, the clinical manifestations of our patient were mild, only with mucocutaneous bleeding. Consequently, the outcome was successful after prompt diagnosis, ITP and treatment with glucocorticoids and intravenous IG.

COVID-19 has been linked to ITP. For instance, in September 2020, Bhattacharjee wrote a systemic review of 45 patients with COVID-19-related ITP. Still, only two cases of this possible association between COVID-19 vaccination and ITP have been reported, one in a medical journal and another in the press.

Vaccines are among the most important inventions in science history and as any other pharmaceutical product should comply with postmarket regulations, including the design and operation of postmarket surveillance systems. In México, the federal government has established a protocol for the report of Events Supposedly Attributable to Vaccination or Immunization (ESAVI) and our case has been reported.
reported as a severe ESAVI according to the national regulations. Further investigation is needed in order to establish if ITP is or not associated with the vaccine. Moreover, ITP onset after receiving a vaccine may not be a reason to discourage the vaccination, since it is a previously reported phenomenon. Nevertheless, there should be caution in patients with previous ITP.

Learning points

► Secondary immune thrombocytopenia can be associated with the COVID-19 RNA vaccine.
► Immune thrombocytopenia (ITP) should not be a reason to discourage vaccination against SARS-CoV-2.
► Although ITP following other vaccines has been previously reported, we still do not know the incidence of such adverse reaction linked to messenger RNA COVID-19 vaccine BNT162b2 (Pfizer–BioNTech).

Acknowledgements We acknowledge Miss. Olivia Gonzalez for English proofreading support.

Contributors BV-A, OF-R and RJ-S conceived the idea and design of the article. OF-R, RJ-S, VN-Y, SIA, RTG, MAGS and BV-A contributed to the preparation and review of the initial manuscript. BV-A drafted the final work and reviewed it critically. All authors approved the final version.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Obtained.

Provenance and peer review Not commissioned; externally peer reviewed.

This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

ORCID iD Benjamin Valente-Acosta http://orcid.org/0000-0001-9885-3594

REFERENCES

1. ECDC. Situation updates on COVID-19. European centre for disease prevention and control, European Union. Solna, Sweden, 2020. Available: https://www.ecdc.europa.eu/en/covid-19/situation-updates [Accessed 02 Feb 2021].

2. Gobierno de México. COVID-19, daily technical report. Mexico’s Ministry of health. Mexico, 2021. Available: https://www.gob.mx/cms/uploads/attachment/file/613408/Comunicado_Tecnico_Diario_COVID-19_2021_02_01.pdf [Accessed 02 Feb 2021].

3. FDA. Emergency use Authorization (EUA) for emergency use of Pfizer-BioNTech COVID-19 vaccine. U.S. food and drug administration. USA, 2020. Available: https://www.fda.gov/media/144412/download [Accessed 02 Feb 2021].

4. Mexico Ministry of health. Emergency use Authorization (Mexico) for Pfizer-BioNTech COVID-19 vaccine. Mexico, 2020. Available: https://www.gob.mx/cofepris/articulos/la-cofepris-otorga-autorizacion-para-uso-de-emergencia-a-vacuna-para-prevenir-la-enfermedad-por-coronavirus-covid-19 [Accessed 02 Feb 2020].

5. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med 2020;383:2603–15.

6. Berlin JA, Glasser SC, Ellenberg SS. Adverse event detection in drug development: recommendations and obligations beyond phase 3. Am J Public Health 2008;98:1366–71.

7. Terrell DR, Beebe LA, Vesely SK, et al. The incidence of immune thrombocytopenic purpura in children and adults: a critical review of published reports. Am J Hematol 2010;85:NA–180.

8. Perricone C, Cecarelli F, NESHER G, et al. Immune thrombocytopenic purpura (ITP) associated with vaccinations: a review of reported cases. Immunol Res 2014;60:226–35.

9. Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Haematologica 2014;99:243–4.

10. Aranes M, Arantes H. Immune thrombocytopenia in a 22-year-old post Covid-19 vaccine. Am J Hematol 2021;96:E133–4.

11. Rothman KJ, Greenland S. Causation and causal inference in epidemiology. Am J Public Health 2005;95 Suppl 1:S144–50.

12. Akbik M, Nadeed H, Ashour AA, et al. Severe immune thrombocytopenia following MMR vaccination with rapid recovery: a case report and review of literature. Int Med Case Rep J 2020;13:697–9.

13. Cecinati V, Principi N, Brescia L, et al. Vaccine administration and the development of immune thrombocytopenic purpura in children. Hum Vaccin Immunother 2013;9:1158–62.

14. David P, Shoenfeld Y. Itp following vaccination. Int J Infect Dis 2020;99:243–4.

15. Kerney B, Stack G. Drug-Induced thrombocytopenia. Arch Pathol Lab Med 2009;133:309–14.

16. Bhattacharjee S, Banerjee M. Immune thrombocytopenia secondary to COVID-19: a systematic review. Syst Compr Clin Med 2020;2:2048–58.

17. Grady D, Mazeei P. Doctor’s Death After Covid Vaccine is Being Investigated. The New York Times. Available: https://www.nytimes.com/2021/01/12/health/covid-vaccine-death.html [Accessed 30 Jan 2021].

18. FDA. Best practices in drug and biological product post-market safety surveillance for FDA staff U.S. food and drug administration. USA, 2019. Available: https://www.fda.gov/media/130216/download [Accessed 02 Feb 2021].

19. Mexico Ministry of Health. Manual de procedimientos estandarizados para La vigilancia epidemiológica de Los eventos supuestamente atribuibles a la vacunación O inmunización (ESAVI) 2021. México, 2021. Available: https://epidemiologia.salud.gob.mx/pboms/salud/documentos/manuales/42_Manual_ESAVI_210127.pdf [Accessed 02 Feb 2021].